Executive summary
US Patent 10,758,550 claims a pediatric (≥2 years) twice-daily intranasal fixed-dose combination of mometasone furoate (MF) and olopatadine hydrochloride (OLOP), at specific per-spray amounts (25 mcg MF + 665 mcg OLOP), with claimed faster onset of symptom relief than either monotherapy at the listed doses, and with time-to-relief thresholds (≤15 min and ≤10 min in dependent claims). The claims are method-of-treatment and method-of-providing faster onset claims, driven by: (1) the combination and dose ratio, (2) the pediatric age range, (3) twice-daily dosing with “one spray per nostril”, and (4) clinical endpoint timing (faster than MF-alone or OLOP-alone; within 15 or 10 minutes).
Below is a scope-and-landscape analysis structured for freedom-to-operate (FTO), licensing, and generic or settlement-risk assessment in the US.
US Patent 10,758,550: Scope, Claim Boundaries, and US Patent Landscape for Pediatric Intranasal Mometasone Furoate + Olopatadine Combination
What is the scope of claims 1–32 in US Patent 10,758,550?
Core claim concept: a method that delivers faster symptom relief of allergic rhinitis in pediatric humans via a specific intranasal dosing regimen of MF + OLOP.
Claim 1 scope (independent)
Claim 1 covers:
- Population: pediatric human subject in need of relief of allergic rhinitis (later claims add minimum age; claim 1 itself is “pediatric human”).
- Route/dose form: intranasal nasal administration.
- Dosing frequency and administration geometry: twice daily, one spray per nostril.
- Fixed-dose composition per spray: about 25 mcg mometasone furoate + about 665 mcg olopatadine HCl.
- Timing/clinical requirement: administration provides relief of one or more allergic rhinitis symptoms faster than nasal administration of 25 mcg MF or 665 mcg OLOP alone (same route, same comparator doses).
Practical claim boundary: a product must both (a) match the exact per-nostril spray dosing and (b) be associated with a comparative faster onset versus monotherapy at the same comparator doses.
Claims 2–3 scope (symptoms limited to nasal symptoms)
- Claim 2: nasal symptoms.
- Claim 3: nasal symptoms selected from nasal congestion, rhinorrhea, itching, and sneezing.
Claims 4–6 scope (age sub-ranges)
- Claim 4: 2 to under 12 years
- Claim 5: 2 to under 6 years
- Claim 6: 6 to under 12 years
Claims 7–9 scope (allergic rhinitis type)
- Claim 7: seasonal, perennial, or persistent allergic rhinitis.
- Claim 8: seasonal allergic rhinitis.
- Claim 9: perennial allergic rhinitis.
Claims 10–12 scope (independent-to-dependent pivot: specific “within X minutes”)
- Claim 10: pediatric subject 2 years or older.
- Claim 11: twice daily, one spray per nostril; 25 mcg MF + 665 mcg OLOP; provides relief within 15 minutes.
- Claim 12: same as claim 11 but relief within 10 minutes.
Practical claim boundary: if clinical evidence supports only a longer onset, a generic might argue it does not meet the endpoint timing requirement for “within 15/10 minutes.” For infringement, though, patent enforceability will often turn on how “provides relief within X minutes” is met for the claimed regimen and whether the patent holder can connect the regimen to those timing outcomes.
Claims 13–22 scope (symptom/allergic rhinitis type constrained within the 2+ pediatric group)
- Claims 13–14: nasal congestion/rhinorrhea/itching/sneezing within the claim 10 structure.
- Claims 15–17: age bands.
- Claims 18–22: seasonal vs perennial vs persistent.
Claims 23–25 scope (single “dose” per administration: higher per-dose amounts)
These claims shift from “one spray per nostril” to “twice daily nasal administration of a single dose,” defining the single dose as twice the per-spray amounts:
- Per single dose: about 1330 mcg OLOP and about 50 mcg MF.
- Timing: relief within 15 minutes (claim 23) or within 10 minutes (claim 24).
- Faster onset comparator (claim 25): faster than monotherapy at 50 mcg MF or 1330 mcg OLOP alone.
Practical note for product design: this section targets the formulation label/pack instruction that maps to a “single dose” concept delivering double the per-nostril spray totals.
Claims 26–32 scope (dependents of claim 25)
- Claim 26–28: age sub-ranges.
- Claim 30: nasal symptoms category.
- Claim 31–32: seasonal or perennial allergic rhinitis.
What patents protect “faster onset” pediatric allergic rhinitis using MF + OLOP?
Based on the claim structure, the patent estate is likely anchored around three invention themes:
- Fixed-dose combination of MF and OLOP for intranasal allergic rhinitis, including dosing regimens.
- Pediatric use (≥2 years) with specified dosing frequency and age bands.
- Clinical timing endpoints (10- and 15-minute relief; “faster than” MF-alone or OLOP-alone comparators).
US Patent 10,758,550 is a method patent, so enforcement risk clusters around:
- Labeling that instructs or permits the claimed pediatric regimen and timing expectations; and
- Evidence that the marketed use meets the endpoint (especially within 10 or 15 minutes).
Adjacent claim themes typically covered by additional patents
In similar combination landscapes, additional US patents often cover:
- Composition/formulation specifics (particle, suspension, preservative system).
- Device and administration method (spray/actuation details).
- Use in allergic rhinitis subtypes (seasonal vs perennial).
- Pediatric-specific dosing instructions.
However, this response is limited to what can be concluded from the claim text provided. Without the patent family list and the Orange Book entries tied to the exact product, the set of additional US patents cannot be enumerated accurately here.
How strong is the patent estate for US 10,758,550 given its “method with timing endpoint” claim style?
Strength drivers:
- Hard numeric dosing: 25 mcg MF + 665 mcg OLOP per spray; and 50 mcg MF + 1330 mcg OLOP per “single dose.”
- Hard regimen structure: twice daily; one spray per nostril; pediatric (≥2 years).
- Endpoint constraints: “within 15 minutes” and “within 10 minutes,” plus “faster than monotherapy” comparators.
Weakness drivers (in litigation posture, not as legal conclusions):
- Proving “faster onset” can be evidentiary. A defendant may contest whether the generic or alternate regimen truly achieves the claimed timing thresholds.
- Design-around by regimen: if a competitor uses the same drugs but a different dose, different dosing frequency, or avoids the “one spray per nostril” structure, the claim language can be difficult to map.
Enforcement consequence:
- A “generic” that matches MF + OLOP concentrations but deviates in endpoint outcome or dosing geometry can create claim non-infringement arguments.
What generic entry risks exist for products competing with the MF + OLOP pediatric intranasal regimen?
US method claims generally create different risk patterns than composition claims:
If a generic seeks approval via ANDA or 505(j)
- Method claims are not always directly implicated by mere submission.
- Real infringement risk often attaches after commercial manufacture/sale when clinicians and patients follow instructions.
Key infringement trigger in this patent
The claim is not only about using MF and OLOP intranasally. It requires:
- pediatric ≥2 years,
- twice daily dosing, and
- timed onset outcome (within 10 or 15 minutes or faster than monotherapies at specified doses).
Practical risk: if a generic’s label or prescribing information supports a regimen substantially identical to the claimed one and the clinical effect is comparable, plaintiffs can pursue infringement theories grounded in “use that meets the claim.”
What is the Orange Book status of US 10,758,550 and the listed MF + OLOP products?
The provided input includes US Patent 10,758,550 claim text only, not the corresponding NDA/ANDA product numbers, listing status, or the Orange Book entry.
Because patent-to-product mapping is required to state Orange Book status and expiration posture precisely, a complete and accurate Orange Book status statement cannot be produced from the information provided.
When does US 10,758,550 lose exclusivity in the US?
A full exclusivity/timeline requires:
- the grant date, filing date, and priority chain of US 10,758,550,
- any term adjustments,
- any PTE (patent term adjustment/extension) linked to an NDA,
- and whether any other family members control.
The input provides only the claim text, not bibliographic data needed to calculate and assert expiration.
What is the litigation landscape around US Patent 10,758,550 and similar MF + OLOP pediatric patents?
Litigation risk assessment requires:
- case numbers,
- parties,
- court,
- asserted claims and construction,
- settlement terms (if any),
- and status.
No litigation docket facts are included in the prompt. A complete and accurate litigation landscape cannot be produced from the information provided.
How do claims 1–12 compare with claims 23–25 (spray-per-nostril vs “single dose”)?
They are aligned but drafted in two formats:
- Claims 1–3, 4–6, 7–12 use per-spray per-nostril quantities: 25 mcg MF + 665 mcg OLOP per spray with “one spray per nostril.”
- Claims 23–25 use a single-dose total that corresponds to delivering both nostrils in the same dosing event: 50 mcg MF + 1330 mcg OLOP per single dose.
Design-around implication: If a competitor’s dosing instruction maps to a different “single dose” definition, or uses a different per-nostril actuation volume, the mapping to the claim’s defined quantities may be contested.
Which allergic rhinitis phenotypes are covered (seasonal vs perennial vs persistent)?
The claims explicitly cover:
- seasonal allergic rhinitis
- perennial allergic rhinitis
- persistent allergic rhinitis
This matters for:
- label indications,
- clinical trial endpoint stratification, and
- whether clinical evidence used to establish timing “within 10/15 minutes” supports all subtypes.
How should R&D teams interpret “faster than monotherapy at the same dose” for infringement and claim charts?
Claim 1 and claim 25 each include a comparator requirement:
- faster than MF alone at 25 mcg (claim 1) or 50 mcg (claim 25), and
- faster than OLOP alone at 665 mcg (claim 1) or 1330 mcg (claim 25).
For infringement analysis, claim mapping commonly turns on:
- whether the accused regimen uses the claimed combination at the claimed per-nostril or single-dose amounts; and
- whether the accused product’s effect is “faster” under the same symptom and endpoint definitions used in the patent.
For validation, teams typically align:
- symptom definitions (nasal congestion/rhinorrhea/itching/sneezing, where limited),
- assessment timepoints (10 and 15 minutes), and
- study population age bands (≥2; 2 to under 6; 6 to under 12, where relevant).
Key Takeaways
- US 10,758,550 is a pediatric intranasal method-of-treatment patent for twice-daily MF + OLOP at fixed doses with endpoint timing constraints.
- The claims are tightly defined by dose geometry (one spray per nostril) and dose amounts (25/665 mcg per spray; 50/1330 mcg per single dose).
- Enforceability and infringement risk hinge on the claim’s clinical timing language: within 10 minutes, within 15 minutes, and faster than monotherapy at the comparator doses.
- Scope coverage includes nasal symptoms and seasonal/perennial/persistent allergic rhinitis.
- A complete Orange Book/exclusivity and litigation landscape cannot be stated from the claim text alone.
FAQs
Do the claims cover adults or only pediatric patients?
The claims are drafted for “pediatric human subject,” with dependent claims specifying 2 years or older and age bands 2 to under 6 and 6 to under 12.
Is “faster onset” required to be within 10 or 15 minutes to infringe?
Claim 1 requires “faster than” MF-alone or OLOP-alone at specified doses; claims 11–12 and 23–24 additionally require relief within 15 minutes or within 10 minutes.
Does infringement depend on which allergic rhinitis subtype the patient has?
The base claim is for allergic rhinitis; dependents explicitly cover seasonal, perennial, and persistent rhinitis.
Can a product with the same drugs but different per-nostril dosing avoid infringement?
Changing the per-spray or single-dose amounts or the dosing structure away from the claim’s defined regimen can be a basis for non-mapping to the exact claim language.
Are symptom categories limited to nasal congestion, rhinorrhea, itching, and sneezing?
Those are in dependent claims. The independent claims cover “one or more symptoms,” with dependent claims narrowing to specific nasal symptoms.
References (APA)
- United States Patent 10,758,550. (Claim text provided in prompt).
